Literature DB >> 8156241

Professional rehabilitation of lymphoma patients: a study of psychosocial factors associated with return to work.

D Razavi1, N Delvaux, A Brédart, P Autier, D Bron, L Debusscher, P Stryckmans.   

Abstract

During the last ten years a substantial reduction in mortality has been obtained for Hodgkin's and non-Hodgkin's lymphoma. Since lymphoma treatment is often accompanied by side effects and long-term sequelae, however, patients often have problems with rehabilitation. It is thus very important that these problems and needs be identified. Going back to work is one of the main objectives of rehabilitation and can be taken as a valuable indicator of the problems and needs of such patients. We therefore conducted a study at the Jules Bordet Institute between December 1989 and December 1990. Of the patients in remission and able to go back to work, only 54% of them have done so. Anxiety, depression, and treatment toxicity interfere with return to work, and the likelihood of job reentry increases with the time lapse since the end of treatment. Rehabilitation programs must focus on alleviating illness and treatment sequelae as soon as treatment ends.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8156241     DOI: 10.1007/bf00366050

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  4 in total

1.  Psychological problems associated with diagnosis and treatment of lymphomas. II: Prospective study.

Authors:  J Devlen; P Maguire; P Phillips; D Crowther
Journal:  Br Med J (Clin Res Ed)       Date:  1987-10-17

2.  Psychological problems associated with diagnosis and treatment of lymphomas. I: Retrospective study.

Authors:  J Devlen; P Maguire; P Phillips; D Crowther; H Chambers
Journal:  Br Med J (Clin Res Ed)       Date:  1987-10-17

3.  Screening for psychiatric disorders in a lymphoma out-patient population.

Authors:  D Razavi; N Delvaux; A Bredart; M Paesmans; L Debusscher; D Bron; P Stryckmans
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

4.  The hospital anxiety and depression scale.

Authors:  A S Zigmond; R P Snaith
Journal:  Acta Psychiatr Scand       Date:  1983-06       Impact factor: 6.392

  4 in total
  6 in total

1.  Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up time--a population-based comparative study.

Authors:  I Glimelius; S Ekberg; J Linderoth; M Jerkeman; E T Chang; M Neovius; K E Smedby
Journal:  J Cancer Surviv       Date:  2015-02-18       Impact factor: 4.442

2.  Impact of cancer on work and education among adolescent and young adult cancer survivors.

Authors:  Helen M Parsons; Linda C Harlan; Charles F Lynch; Ann S Hamilton; Xiao-Cheng Wu; Ikuko Kato; Stephen M Schwartz; Ashley W Smith; Gretchen Keel; Theresa H M Keegan
Journal:  J Clin Oncol       Date:  2012-05-21       Impact factor: 44.544

3.  A preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma: the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy - Lymphoma Symptom Index.

Authors:  Fay J Hlubocky; Kimberly Webster; Jennifer Beaumont; John Cashy; Diane Paul; Amy Abernethy; Karen L Syrjala; Jamie Von Roenn; David Cella
Journal:  Leuk Lymphoma       Date:  2013-02-07

4.  The need for online information on the economic consequences of cancer diagnosis, treatment, and survivorship.

Authors:  Cathy J Bradley
Journal:  J Med Internet Res       Date:  2005-07-01       Impact factor: 5.428

Review 5.  Psychological problems among cancer patients in relation to healthcare and societal costs: A systematic review.

Authors:  Florie E Van Beek; Lonneke M A Wijnhoven; Karen Holtmaat; José A E Custers; Judith B Prins; Irma M Verdonck-de Leeuw; Femke Jansen
Journal:  Psychooncology       Date:  2021-07-06       Impact factor: 3.955

6.  What do cancer patients mean when they complain of concentration and memory problems?

Authors:  A Cull; C Hay; S B Love; M Mackie; E Smets; M Stewart
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.